Home World News EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim World News EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 487 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Teen Quarterback Scores 8 Touchdowns A Day After His Mom Dies... November 20, 2021 Bus Driver Finds Out Teen With Cancer Can’t Afford Prom &... June 19, 2019 Advanced and Metastatic Prostate Cancer Living Guideline June 11, 2026 News digest – ovarian cancer blood test, statins, spending review and... October 31, 2020 Load more HOT NEWS Hugh Jackman Stops His Show To Bring Woman With Breast Cancer... Survivorship and Immune Checkpoint Inhibitors Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests EMA Recommends Granting a Marketing Authorisation for Tislelizumab
